MTOR and central nervous system cancer: Chandrika et al. demonstrated that mTOR inhibitors like temsirolimus and torin significantly reduce the expression levels of mesenchymal markers (fibronectin, vimentin, and YKL40) and neural stem cell markers (Sox2, Oct4, nestin, and mushashi1) induced by the tumor promoter phorbol-myristate-acetate in LN-18 glioma cells, through the dephosphorylation of the transcriptional factor STAT3 [273].